Cargando…

The Therapeutic Potential for PI3K Inhibitors in Autoimmune Rheumatic Diseases

The class 1 PI3Ks are lipid kinases with key roles in cell surface receptor-triggered signal transduction pathways. Two isoforms of the catalytic subunits, p110γ and p110δ, are enriched in leucocytes in which they promote activation, cellular growth, proliferation, differentiation and survival throu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Banham-Hall, Edward, Clatworthy, Menna R, Okkenhaug, Klaus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bentham Open 2012
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3460535/ https://www.ncbi.nlm.nih.gov/pubmed/23028409 http://dx.doi.org/10.2174/1874312901206010245

Ejemplares similares

PI3K inhibitors in inflammation, autoimmunity and cancer
por: Stark, Anne-Katrien, et al.
Publicado: (2015)

PI3Kδ hyper-activation promotes development of B cells that exacerbate Streptococcus pneumoniae infection in an antibody-independent manner
por: Stark, Anne-Katrien, et al.
Publicado: (2018)

PI3K Signaling in B Cell and T Cell Biology
por: Okkenhaug, Klaus, et al.
Publicado: (2014)

PI3K Signaling in Normal B Cells and Chronic Lymphocytic Leukemia (CLL)
por: Okkenhaug, Klaus, et al.
Publicado: (2015)

PI3K in T Cell Adhesion and Trafficking
por: Johansen, Kristoffer H., et al.
Publicado: (2021)

Antigen receptor signalling: a distinctive role for the p110δ isoform of PI3K
por: Okkenhaug, Klaus, et al.
Publicado: (2007)

Non-Invasive Multiphoton Imaging of Islets Transplanted Into the Pinna of the NOD Mouse Ear Reveals the Immediate Effect of Anti-CD3 Treatment in Autoimmune Diabetes
por: Benson, Robert A., et al.
Publicado: (2018)

PI3K induces B-cell development and regulates B cell identity
por: Abdelrasoul, Hend, et al.
Publicado: (2018)

PI3Kδ promotes CD4(+) T-cell interactions with antigen-presenting cells by increasing LFA-1 binding to ICAM-1
por: Garçon, Fabien, et al.
Publicado: (2016)

Does the PI3K pathway promote or antagonize regulatory T cell development and function?
por: Soond, Dalya R., et al.
Publicado: (2012)

The PI3K p110δ Regulates Expression of CD38 on Regulatory T Cells
por: Patton, Daniel T., et al.
Publicado: (2011)

Autoimmune Rheumatic Diseases: An Update on the Role of Atherogenic Electronegative LDL and Potential Therapeutic Strategies
por: Chen, Der-Yuan, et al.
Publicado: (2021)

Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics
por: Akinleye, Akintunde, et al.
Publicado: (2013)

PI3Kδ Regulates the Magnitude of CD8(+) T Cell Responses after Challenge with Listeria monocytogenes
por: Pearce, Verity Q., et al.
Publicado: (2015)

Autoimmune Rheumatic Diseases
por: Anaya, Juan-Manuel, et al.
Publicado: (2014)

Metformin and its therapeutic applications in autoimmune inflammatory rheumatic disease
por: Kim, Ji-Won, et al.
Publicado: (2022)

Bromodomain Inhibitors Modulate FcγR-Mediated Mononuclear Phagocyte Activation and Chemotaxis
por: Banham, Gemma D., et al.
Publicado: (2022)

Therapeutic Potency of PI3K Pharmacological Inhibitors of Gastrointestinal Cancer
por: Hashemzadeh, Kamelia, et al.
Publicado: (2019)

Curcumin in Autoimmune and Rheumatic Diseases
por: Yang, Melissa, et al.
Publicado: (2019)

Epigenetic Modulation as a Therapeutic Prospect for Treatment of Autoimmune Rheumatic Diseases
por: Ciechomska, Marzena, et al.
Publicado: (2016)

Autoimmune polyendocrine syndromes associated with autoimmune rheumatic diseases
por: Jankowska, Katarzyna, et al.
Publicado: (2023)

Editorial: Frontiers in Autoimmune Disease: Rheumatic Fever and Rheumatic Heart Disease
por: Guilherme, Luiza, et al.
Publicado: (2015)

PI3K-γ inhibitors in the therapeutic intervention of diseases caused by obligate intracellular pathogens
por: Oghumu, Steve, et al.
Publicado: (2013)

PI3Kδ Forms Distinct Multiprotein Complexes at the TCR Signalosome in Naïve and Differentiated CD4(+) T Cells
por: Luff, Daisy H., et al.
Publicado: (2021)

PI3K inhibitors in thrombosis and cardiovascular disease
por: Durrant, Tom N., et al.
Publicado: (2020)

Targeting Syk in Autoimmune Rheumatic Diseases
por: Deng, Guo-Min, et al.
Publicado: (2016)

Vaccinations in autoimmune inflammatory rheumatic diseases
por: Szenborn, Leszek
Publicado: (2016)

Pneumococcal vaccination in autoimmune rheumatic diseases
por: Rákóczi, Éva, et al.
Publicado: (2017)

Mechanisms of hypertension in autoimmune rheumatic diseases
por: Taylor, Erin B., et al.
Publicado: (2019)

Autoantibody Profiles in Autoimmune Rheumatic Diseases
por: Bizzaro, Nicola
Publicado: (2019)

Cognitive dysfunction in autoimmune rheumatic diseases
por: Oláh, Csaba, et al.
Publicado: (2020)

Vitamin D and Autoimmune Rheumatic Diseases
por: Athanassiou, Lambros, et al.
Publicado: (2023)

Long COVID in autoimmune rheumatic diseases
por: Fedorchenko, Yuliya, et al.
Publicado: (2023)

Circulating Th17 T cells at treatment onset predict autoimmune toxicity of PI3Kδ inhibitors
por: Gadi, Deepti, et al.
Publicado: (2023)

Anti-CTLA-4 (CD 152) monoclonal antibody-induced autoimmune interstitial nephritis
por: Jolly, Elaine C., et al.
Publicado: (2009)

PI3K inhibitors as new cancer therapeutics: implications for clinical trial design
por: Massacesi, Cristian, et al.
Publicado: (2016)

Characterization of Novel PI3Kδ Inhibitors as Potential Therapeutics for SLE and Lupus Nephritis in Pre-Clinical Studies
por: Haselmayer, Philipp, et al.
Publicado: (2014)

The therapeutic potential of targeting the PI3K pathway in pediatric brain tumors
por: Rogers, Hazel A., et al.
Publicado: (2016)

Autoimmune Rheumatic Diseases and Vascular Function: The Concept of Autoimmune Atherosclerosis
por: Hedar, Ahmed M., et al.
Publicado: (2021)

Autoimmune rheumatic diseases: One or many diseases?
por: Moutsopoulos, Haralampos M.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_odlao6kau4t3tpg4n8t7pej3gl